抄録
Prediabetes, typically defined as impaired glucose tolerance, is a high-risk state of developing diabetes. Although there have considerable scientific progresses in related areas, the extended research concerning antidiabetic action of natural compounds at prediabetic stage has been limited due to the lack of specific biomarkers that enable to identify prediabetes state and elucidate the complicated mechanism of antidiabetic action of natural compounds. The increased formation and accumulation of advanced glycation end products (AGEs) have been confirmed as a vital risk of developing hyperglycemia, type 2 diabetes, and diabetic complications. Many researches revealed that AGEs have showed great potential to be served as biomarkers to predict prediabetic condition. The present chapter is aimed to offer an overview of prediabetes and the current research outcomes involved with functionally natural compounds in decreasing the risk of developing diabetes at prediabetic stage.
| 元の言語 | 英語 |
|---|---|
| ホスト出版物のタイトル | Discovery and Development of Antidiabetic Agents from Natural Products |
| ホスト出版物のサブタイトル | Natural Product Drug Discovery |
| 出版者 | Elsevier Inc. |
| ページ | 209-228 |
| ページ数 | 20 |
| ISBN（電子版） | 9780128096925 |
| ISBN（印刷物） | 9780128094501 |
| DOI | |
| 出版物ステータス | 出版済み - 1 1 2017 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Chemistry(all)
これを引用
Prediction of Prediabetes and its Prevention by Functional Food Compounds. / Chen, S. J.; Matsui, Toshiro.
Discovery and Development of Antidiabetic Agents from Natural Products: Natural Product Drug Discovery. Elsevier Inc., 2017. p. 209-228.研究成果: 著書/レポートタイプへの貢献 › 章
}
TY - CHAP
T1 - Prediction of Prediabetes and its Prevention by Functional Food Compounds
AU - Chen, S. J.
AU - Matsui, Toshiro
PY - 2017/1/1
Y1 - 2017/1/1
N2 - Prediabetes, typically defined as impaired glucose tolerance, is a high-risk state of developing diabetes. Although there have considerable scientific progresses in related areas, the extended research concerning antidiabetic action of natural compounds at prediabetic stage has been limited due to the lack of specific biomarkers that enable to identify prediabetes state and elucidate the complicated mechanism of antidiabetic action of natural compounds. The increased formation and accumulation of advanced glycation end products (AGEs) have been confirmed as a vital risk of developing hyperglycemia, type 2 diabetes, and diabetic complications. Many researches revealed that AGEs have showed great potential to be served as biomarkers to predict prediabetic condition. The present chapter is aimed to offer an overview of prediabetes and the current research outcomes involved with functionally natural compounds in decreasing the risk of developing diabetes at prediabetic stage.
AB - Prediabetes, typically defined as impaired glucose tolerance, is a high-risk state of developing diabetes. Although there have considerable scientific progresses in related areas, the extended research concerning antidiabetic action of natural compounds at prediabetic stage has been limited due to the lack of specific biomarkers that enable to identify prediabetes state and elucidate the complicated mechanism of antidiabetic action of natural compounds. The increased formation and accumulation of advanced glycation end products (AGEs) have been confirmed as a vital risk of developing hyperglycemia, type 2 diabetes, and diabetic complications. Many researches revealed that AGEs have showed great potential to be served as biomarkers to predict prediabetic condition. The present chapter is aimed to offer an overview of prediabetes and the current research outcomes involved with functionally natural compounds in decreasing the risk of developing diabetes at prediabetic stage.
UR - http://www.scopus.com/inward/record.url?scp=85024932986&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85024932986&partnerID=8YFLogxK
U2 - 10.1016/B978-0-12-809450-1.00007-7
DO - 10.1016/B978-0-12-809450-1.00007-7
M3 - Chapter
AN - SCOPUS:85024932986
SN - 9780128094501
SP - 209
EP - 228
BT - Discovery and Development of Antidiabetic Agents from Natural Products
PB - Elsevier Inc.
ER -